treatment | Blood Cancers Today

treatment

Leah SherwoodMyelodysplastic Syndromes | November 15, 2022

There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..

Sagar Lonial, MD, FACPPrint | June 23, 2022

ASCO, EHA, and other medical society meetings represent the best of who we are—people working together toward a common ...

Leah LawrencePrint | November 14, 2022

Blood Cancers Today recently spoke with leaders in the field about what they have learned—and what still needs to be ...

Kerri FitzgeraldMyeloma | February 3, 2023

Authors provide a case that demonstrates the real-world challenges of managing older, frail adults with newly diagnosed MM.

Leah LawrenceAggressive B-Cell Lymphoma | November 14, 2022

Patients with different subtypes of B-cell non-Hodgkin lymphoma experience different treatment outcomes.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer